Navigation Links
Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
Date:3/28/2011

SAN DIEGO, March 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data highlighting the burden of Clostridium difficile infection using National health insurance claims and survey databases will be presented on April 2, 2011 at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA).  

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)Poster Presentation Information:Title:

Rates of Recurrence and Mortality among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey DatabasesPresenter:

Erik R. Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MODate:

Saturday, April 2, 2011 Time:

1:00 p.m. to 2:15 p.m. Central TimeLocation:

Hilton Anatole Hotel, Trinity Ballroom, Dallas, TexasPresentation #:

152About OptimerOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
2. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
4. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
5. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
7. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
8. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Optimer Pharmaceuticals Announces Key Additions to Management Team
11. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec 2, 2016 Research and Markets has ... newsletter to their offering. ... , R&D Drug Pipeline ... proprietary R&D Drug Pipeline Database provides 24/7 online access to information ... the market and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
(Date:12/2/2016)... SPRINGFIELD GARDENS, N.Y. , Dec. 2, 2016 /PRNewswire/ ... victims, will be included in the Emergency Response Training ... "We are very excited to have LifeVac become part ... Arthur Lih , Founder and CEO of LifeVac. "Having ... use LifeVac safely and effectively will help leverage our ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Airy Jeanine is putting ... Songwriter-Producer Corey “Chorus” Gibson who has worked on hits by mega-artists like Rihanna, ... https://twitter.com/coreychorus , The sessions taking place in North Jersey’s Cybertime Studios ...
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish ... take advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional ... appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity ...
Breaking Medicine News(10 mins):